🔎 Trials Near Me

Beranda › Purpura Trombositopenik Idiopatik › Massachusetts

Uji klinis Purpura Trombositopenik Idiopatik di Massachusetts

6 studi untuk Purpura Trombositopenik Idiopatik mencari peserta di lokasi di Massachusetts.

Kota di Massachusetts

Teks studi resmi (Bahasa Inggris)

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  • Massachusetts General Hospital, Boston
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT06722235

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

  • Beth Israel Deaconess Medical Center, Boston
Menerima pesertaFase 2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT07095127

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

  • Beth Israel Deaconess Medical Center, Boston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT07104565

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  • Massachusetts General Hospital, Boston
  • University of Massachusetts Chan Medical School, Worcester
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06948318

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

  • Massachusetts General Hospital Cancer Center, Boston
  • Beth Israel Deaconess Medical Center, Boston
  • Mass General Brigham Cancer Institute, Danvers
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jun 2026 · NCT07007962

Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia

  • Massachusetts General Hospital, Boston
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Feb 2025 · NCT06817395

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.